Clinical trial · Interventional
MG98 in Treating Patients With Advanced Solid Tumors
A Phase I Study of MG98 Given as a 2 Hour Twice Weekly IV Infusion in Patients With Advanced Cancer
NCT00003890CI-TRIAL-00044487completedPhase 1ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of MG98 in treating patients who have advanced solid tumors.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Unspecified Adult Solid Tumor, Protocol Specific | Adult Solid Neoplasm | ALIAS | 0.85 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| MG 98 | Drug | — | UNRESOLVED |
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 120 Years
Show eligibility criteria text
DISEASE CHARACTERISTICS: * Histologically or cytologically proven advanced solid tumor unresponsive to existing therapy or for which no curative therapy exists * Evidence of disease in addition to tumor marker elevation * CNS metastases allowed, if adequately treated and symptoms controlled for greater than 4 months PATIENT CHARACTERISTICS: Age: * 18 and over Performance status: * ECOG 0-2 Life expectancy: * At least 12 weeks Hematopoietic: * Absolute granulocyte count at least 1,500/mm3 * Platelet count at least 100,000/mm3 * PTT normal Hepatic: * Bilirubin no greater than 1.25 times upper limit of normal (ULN) * SGOT or SGPT no greater than 3 times ULN (4 times ULN for liver metastases) Renal: * Creatinine no greater than 1.25 times ULN * Proteinuria less than 2+ (no greater than 500 mg in a 24 hour urinalysis) Other: * No active infection * No other serious systemic disease * No known hypersensitivity to oligodeoxynucleotides * Adequate venous access * No known condition (e.g., psychological, geographical) that would prevent compliance * Not pregnant or nursing * Negative pregnancy test * Fertile patients must use effective contraception during and for 3 months after the study PRIOR CONCURRENT THERAPY: Biologic therapy: * No concurrent colony stimulating factors unless evidence of neutropenic infection Chemotherapy: * No more than 3 prior chemotherapy regimens * At least 3 weeks since prior chemotherapy (6 weeks for nitrosoureas and mitomycin) and recovered * At least 1 year since prior high dose chemotherapy with bone marrow or stem cell support * No concurrent chemotherapy Endocrine therapy: * Prior hormonal therapy allowed * No concurrent hormonal therapy Radiotherapy: * At least 4 weeks since prior radiotherapy and recovered * Concurrent palliative radiotherapy allowed Surgery: * At least 2 weeks since prior major surgery Other: * At least 3 weeks since prior investigational drug therapy * No other concurrent investigational drug or anticancer therapy * No concurrent coumadin or heparin therapy
References
Publications (1)
- RESULTStewart DJ, Donehower RC, Eisenhauer EA, Wainman N, Shah AK, Bonfils C, MacLeod AR, Besterman JM, Reid GK. A phase I pharmacokinetic and pharmacodynamic study of the DNA methyltransferase 1 inhibitor MG98 administered twice weekly. Ann Oncol. 2003 May;14(5):766-74. doi: 10.1093/annonc/mdg216. PMID 12702532